July 8, 2001

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655

PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com

FOR IMMEDIATE RELEASE

ZOLL Medical Corporation Announces

Burlington, MA Sunday, July 08, 2001 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of cardiac resuscitation devices which provide defibrillation and pacing, today announced that it has received 510(k) clearance from the FDA for the ZOLL M Series defibrillators with invasive blood pressure (IBP) and temperature (TEMP) monitoring. The ability to monitor IBP and TEMP adds another set of important parameters to the M Series capabilities.

Michael Parascandola, Marketing Director for Hospitals at ZOLL, noted, “The addition of IBP and TEMP positions the M Series as the most compact and lightest integrated transport defibrillator. It eliminates the need for customers to coordinate the use of multiple devices when transporting critically ill patients both within and outside of the hospital.” Mr. Parascandola continued, “This latest addition to the M Series platform is continued evidence of its flexibility, and the wisdom of its investment for customers.”

This latest release makes it possible for M Series customers to add two channels each of invasive pressure monitoring and body temperature measurement. The new technology is compatible with commonly available pressure transducers and temperature probes. The size and footprint of the M Series does not change with these added functions.

Richard A. Packer, President and Chief Executive Officer commented, “The addition of IBP and TEMP to the M Series is another important step in continuing ZOLL’s growth in market share, in both the hospital and pre-hospital markets. It gives ZOLL the opportunity to expand into a growing niche for critical care transport. We expect to begin shipments at the end of the calendar year.”

ZOLL Medical Corporation designs, manufactures and markets and integrated line of proprietary non-invasive resuscitation devices and disposable electrodes. Used by healthcare professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical services.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company’s business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company’s business model and future operating performance of the Company, including expectations regarding results in future periods, growth in market share, the time-frame for beginning product shipments and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed on May 16, 2001.

News Room Resources

July 8, 2001

Related Info